NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
February 14, 2026 — Peptide Protocol Wiki launches comprehensive peer-reviewed database with free access to peptide research, safety data, and protocol guidance for BPC-157, GLP-1 agonists, and more.
February 14, 2026 — QuickMed CEO Lena Esmail advocates for school-based health clinics to combat student absenteeism and health disparities. Learn how these clinics improve attendance and access to care.
February 14, 2026 — Taquarius Ford, an incarcerated author, releases The GWiz Series on Amazon, children's books for kids with incarcerated parents. Illustrated by Kenya Kelly.
February 14, 2026 — Friendly Recovery Center's new blog clarifies differences between hyperfixation and addiction. Learn how to distinguish these behaviors and when to seek a mental health therapist for guidance.
February 13, 2026 — HeartBeam Inc. recognized in Modern Healthcare report for FDA-cleared cardiac diagnostic technology. The company's cable-free ECG system advances arrhythmia assessment with innovative three-direction signal capture.
February 13, 2026 — LIXTE Biotechnology announces progress in cancer therapy LB-100 while sponsoring health equity summit. Learn about their novel PP2A inhibitor and community health initiatives.
February 13, 2026 — Helus Pharma announces Q3 2025 financial results, highlighting progress in Phase 3 HLP003 for depression and Phase 2 HLP004 for anxiety, with $195.1M cash and key clinical milestones ahead.
February 13, 2026 — Nutex Health reopens Bayou City ER & Hospital in Texas, expanding 24/7 concierge care with advanced imaging and specialized services to serve Humble and Kingwood communities.
February 13, 2026 — Israeli-led study discovers why breast cancer metastasizes to brain, offering new treatment possibilities. Research could benefit companies like CNS Pharmaceuticals developing novel therapies.
February 13, 2026 — Earth Science Tech (ETST) transforms holding company model with active healthcare management. Learn about their vertically integrated portfolio and growth strategy in health and wellness sector.
February 13, 2026 — GeoVax Labs announces a $1 million registered direct offering to fund clinical trials for COVID-19 vaccines and cancer therapies, advancing treatments for immunocompromised patients and solid tumors.
February 12, 2026 — ROTH Capital hires three executives to strengthen its healthcare investment banking, institutional sales, and equity research platforms, enhancing services for life sciences companies.
February 12, 2026 — LIXTE Biotechnology's LB-100 targets PP2A to enhance chemotherapy & immunotherapy effectiveness in cancer treatment. Clinical trials underway for ovarian & colon cancers.
February 12, 2026 — Jupiter Neurosciences partners with B2i Digital to enhance investor visibility. The biotech firm is advancing a Phase IIa Parkinson's trial and expanding its Nugevia™ longevity brand.
February 12, 2026 — HeartBeam (BEAT) recognized in Modern Healthcare & PatentVest reports for its FDA-aligned, cable-free ECG system. Learn about this cardiac diagnostic innovation.
February 12, 2026 — Annovis Bio receives positive DSMB safety review for Phase 3 Alzheimer's trial of buntanetap, supporting continuation without modification. Read key updates.
February 12, 2026 — Oncotelic Therapeutics and Sapu Bioscience announce expanded IP for OT-101, a TGF-β antisense platform for Parkinson's Disease treatment, with patents in Australia, China, and Germany.
February 12, 2026 — NanoViricides files for FDA Orphan Drug Designation for NV-387 to treat MPox, offering potential incentives and market exclusivity amid global health concerns.
February 12, 2026 — Therapy Group of DC expands mental health services in Washington, D.C., offering therapy, telehealth, and affordable care to address stress and anxiety. Learn more about their evidence-based approach.
February 12, 2026 — Soligenix updates shareholders on 2026 milestones for rare disease pipeline, including Phase 3 CTCL trial data, strategic evaluations, and a $10.5M cash position. Learn more about HyBryte and vaccine candidates.